The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).

Topic PTSD
Compound Psilocybin
Country United Kingdom
Visit trial
Status Recruiting
Results Published
Start date 11 April 2022
End date 21 August 2023
Chance of happening 89%
Phase Phase II
Design Open
Type Interventional
Generation Second
Participants 29
Sex All
Age 18- 99
Therapy No

Trial Details

The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).

NCT Number NCT05312151

Sponsors & Collaborators

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.

King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.

Measures Used

Clinician-Administered PTSD Scale for DSM-5
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is often considered the gold standard in PTSD assessment. The 30-item structured interview was developed by staff at the U.S. Department of Veterans Affairs National Centre for PTSD. CAPS can be used to make a current diagnosis, lifetime diagnosis or assess PTSD symptoms over the past week in accordance with DSM-5 criteria.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.